SCHEMBL2173517

SCHEMBL2173517

NCc1nc(C(=O)NCCc2cccc(Cl)c2)c[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.54
SMN1; SMN2 Q16637 5/20 0.51
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
GAA P10253 1/20 0.51
HTT P42858 1/20 0.50
ADORA2A P29274 1/20 0.50
ADORA1 P30542 1/20 0.50
ALDH1A1 P00352 4/20 0.48
HPGD P15428 1/20 0.48
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CNR1 P21554 2/20 0.46
TAAR1 Q96RJ0 1/20 0.46
TRPV1 Q8NER1 1/20 0.46
PLAAT3 P53816 1/20 0.46
PLAAT5 Q96KN8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12484646 0.86 NPC1 (0.48) HIF1ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL2172312 0.81 KDM4E (0.48) HIF1ASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL2171406 0.78 SMN1; SMN2 (0.57) HIF1ASMN1; SMN2NPC1RAB9AKMT2A
Hydrochloric Acid SCHEMBL2173104 0.77 SMN1; SMN2 (0.56) HIF1ASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL2174882 0.77 HIF1A (0.54) HIF1ASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL2174455 0.77 MAPT (0.60) HIF1ASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL4383737 0.75 TRPV1 (0.58) HIF1ASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL937744 0.73 HIF1A (0.63) HIF1ASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL13210596 0.72 HIF1A (0.72) HIF1ASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL5216536 0.71 KMT2A (0.65) HIF1ASMN1; SMN2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 HIF1A 1345/4885SMN1; SMN2 4564/4885NPC1 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.